Drug intelligence / Profile preview

griseofulvin

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Griseofulvin is an oral antifungal small molecule derived from species of Penicillium. It is primarily used to treat dermatophyte (tinea) infections of the skin, hair, and nails—including tinea capitis (scalp), tinea corporis (body/ringworm), tinea pedis (athlete’s foot), tinea cruris (jock itch), and onychomycosis (nail infections). It acts as a fungistatic agent by binding to fungal microtubules—specifically alpha and beta tubulin—disrupting mitosis in susceptible fungi. Additionally, it binds to keratin precursor cells in human tissue; this makes newly formed keratin resistant to fungal invasion. Its activity is limited to dermatophytes such as Trichophyton, Microsporum, and Epidermophyton species[1][2][3][4][5][6].

Brand names
Grifulvin VFulvicin P/GFulvicin U/FGrisactin UltraGrisactin 500Grisactin500Grisactin-500GrisactinGris-PegUltragrisGriseofulicinGriseofulvic
Other names
AmudaneGriséofulvineGriseofulvinaGriseofulvinumgriseofulvin, microcrystallinegriseofulvin, ultramicrosize
02

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on griseofulvin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on griseofulvin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call